StockData

Huntsman vs Innospec

HUN and IOSP side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HUN and IOSP compare

Innospec is the larger company, worth 1.2 times as much as Huntsman ($2.0B against $1.7B).

Innospec grew revenue faster over the last twelve months (4.7% versus 0.65% for Huntsman).

Both pay dividends: Huntsman yields 3.7% and Innospec 2.2%.

Innospec scores higher on the StockData Score (14 against 3 for Huntsman), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHUNIOSP
Size and price
Market cap$1.7B$2.0B
Share price$9.53$80.39
Change, 1 year12.4%7.4%
Change, 5 years−70.4%−7.9%
Beta (5Y)0.850.86
Employees6,0002,450
StockData Score
Total score314 (better)
Valuation score14 (better)
Growth score01 (better)
Performance score01 (better)
Health score16 (better)
Dividend score12 (better)
Valuation
P/S0.3× (better)1.1×
P/B0.6× (better)1.4×
EV/EBITDA13.8×8.5× (better)
FCF yield−0.54%–
Fair value$8.15$109.30
Margin of safety−16.9%26.5% (better)
Growth
Revenue growth (TTM)0.65%4.7% (better)
Revenue growth, 5Y average0.95%8.3% (better)
EPS growth, 5Y average–32.1%
Profitability
Gross margin13.5%27.7% (better)
Operating margin−0.54%8.8% (better)
Net margin−3.1%–
FCF margin−0.15%–
Return on equity−6.5%–
Return on invested capital−0.57%12.4% (better)
Financial health
Debt / equity0.78 (better)0.00
Net debt / EBITDA6.59–
Current ratio1.332.95 (better)
Altman Z-score1.475.12 (better)
Piotroski F-score2–
Dividends and buybacks
Dividend yield3.7% (better)2.2%
Years of dividend growth012 (better)
Dividend growth, 5Y average5.2%10.5% (better)
Buyback yield–0.68%
Shareholder yield3.7% (better)2.9%
Ownership
Held by institutions88.7%101%
Held by insiders6.7%1.6%
Insider net buying, 12 months$981K (better)−$874K
Short interest, % of float7.4%1.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.